Examkin

Question

Difficulty: Very hardMonitoring and Treatment Evaluation

A 58-year-old man is preparing for discharge from the cardiac intensive care unit. He was admitted 4 days ago for ventricular tachycardia storm, experiencing multiple recurrent implantable cardioverter-defibrillator (ICD) shocks. He was stabilized on an intravenous amiodarone infusion and is now being transitioned to an oral amiodarone loading regimen (400 mg three times daily) to suppress further arrhythmias.

His past medical history is significant for ischemic cardiomyopathy with a left ventricular ejection fraction of 20%, permanent atrial fibrillation, mechanical mitral valve replacement 5 years ago, and stable chronic kidney disease.

His home medications, which were continued throughout his hospitalization, include warfarin 5 mg daily, digoxin 0.125 mg daily, metoprolol succinate 100 mg daily, lisinopril 20 mg daily, and furosemide 40 mg daily.

Today's laboratory results are as follows:

Laboratory TestResultReference / Target
Serum creatinine1.7 mg/dLBaseline 1.6 mg/dL
Serum potassium4.2 mEq/L3.5 - 5.0 mEq/L
INR3.12.5 - 3.5
Serum digoxin0.8 ng/mL0.5 - 0.9 ng/mL

Which of the following is the most appropriate next step in treatment adaptation and monitoring for this patient at discharge?

  1. Reduce both the warfarin and digoxin doses by 30% to 50%, and schedule a follow-up for INR and serum digoxin level checks in 3 to 7 days.Answer
  2. B
    Maintain the current doses of all medications, schedule an INR check in 14 days, and advise the patient to return if palpitations recur.
  3. C
    Discontinue warfarin, initiate a direct oral anticoagulant, reduce the digoxin dose by 50%, and schedule a follow-up in 1 week.
  4. D
    Reduce the warfarin dose by 30% to 50%, maintain the digoxin dose, and order an anti-factor Xa activity assay in 5 days to monitor the anticoagulant effect.
  5. E
    Discontinue lisinopril and furosemide due to the recent rise in serum creatinine, maintain the warfarin and digoxin doses, and recheck a basic metabolic panel in 24 hours.

Answer

Reduce both the warfarin and digoxin doses by 30% to 50%, and schedule a follow-up for INR and serum digoxin level checks in 3 to 7 days.
The correct approach recognizes the potent and predictable pharmacokinetic interactions introduced by amiodarone. Amiodarone strongly inhibits CYP2C9, the primary enzyme responsible for metabolizing the highly active S-enantiomer of warfarin. Concurrently, it inhibits P-glycoprotein, a critical drug efflux pump responsible for the clearance of digoxin. Without preemptive intervention, the amiodarone loading regimen will cause a rapid and dangerous rise in both INR (leading to hemorrhage) and serum digoxin (leading to further ventricular arrhythmias). The standard of care mandates empirical dose reductions of 30% to 50% for both medications upon amiodarone initiation, followed by close laboratory surveillance within 3 to 7 days.

Step-by-Step Solution

1
Identify the critical active medications and the newly added agent.
The patient is on warfarin and digoxin (narrow therapeutic index drugs) and is starting a high-dose amiodarone loading regimen.
Establishing the medication profile is essential for predicting drug-drug interactions.
2
Determine the pharmacokinetic effects of amiodarone on the patient's existing regimen.
Amiodarone inhibits CYP2C9, significantly decreasing warfarin metabolism. It simultaneously inhibits P-glycoprotein, significantly decreasing the renal clearance of digoxin.
Understanding the specific enzymatic pathways affected by amiodarone predicts the trajectory of concomitant drug levels.
3
Formulate a proactive management plan to prevent toxicity.
Empirical reductions of 30% to 50% for both warfarin and digoxin are required, alongside close laboratory monitoring within the first week.
Preemptive dose adjustment prevents bleeding complications and digoxin toxicity (which can trigger further arrhythmias), ensuring safe transitions of care.

Key Concept

Initiation of amiodarone requires empirical dose reductions (typically 30-50%) of both warfarin (due to CYP2C9 inhibition) and digoxin (due to P-glycoprotein inhibition) to prevent severe toxicity.
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic